Acetylon Pharmaceuticals has initiated a Phase I/IIa clinical trial of ACY-1215, an oral Class II histone deacetylase inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

The Phase Ia and Ib portions will evaluate the maximum tolerated dose of ACY-1215 as a monotherapy or in combination with bortezomib and dexamethasone, followed by up to five additional sequential cycles of treatment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Phase IIa portion is designed to determine the objective response rate to ACY-1215 in combination dose for up to six 21-day cycles.

The clinical trial is being conducted by Acetylon in partnership with The Leukaemia & Lymphoma Society.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now